Pharma Exclusives Pressreleases
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Saturday, June 21, 2025The US Food and Drug Administration FDA has approved Dupixent dupilumab for the treatment of adult patients with bullous pemphigoid BP BP primarily affects elderly patients and is characterized by intense itch painful blisters and lesions as well as...
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Saturday, June 21, 2025Rochepresented today results from the phase III SUNMO NCT study showing Lunsumio mosunetuzumab administered subcutaneously in combination with Polivy polatuzumab vedotin demonstrated
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Friday, June 20, 2025Ipsen announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has issued a positive opinion for Cabometyx cabozantinib for adult patients with unresectable
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Thursday, June 19, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announces positive topline clinical results from Part of a Phase b multiple ascending dose MAD trial
NUZ-001 Shows Promise in Zebrafish Model of Huntington’s Disease
Tuesday, June 17, 2025Neurizon Therapeutics Limited a clinicalstage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases is pleased to announce new preclinical data demonstrating
Bayer files for approval of gadoquatrane in the U.S.
Tuesday, June 17, 2025FDA submission seeks approval for investigational low dose gadoliniumbased contrast agent GBCA gadoquatrane for contrastenhanced magnetic resonance imaging MRI of the central nervous system CNS
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Monday, June 16, 2025Roche announced today its decision to proceed with Phase III development of prasinezumab an investigational antialphasynuclein antibody in earlystage Parkinsons disease This decision is informed by data
Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
Monday, June 16, 2025Rocheannounced today new dosing restrictions effective immediately for ELEVIDYS delandistrogene moxeparvovec for nonambulatory Duchenne muscular dystrophy DMD patients irrespective of age
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Monday, June 16, 2025Teva Pharmaceutical Industries Ltd and Shanghai Fosun Pharmaceutical Group Co Ltd today announced that the companies through their respective subsidiaries have entered a strategic partnership for the development
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Friday, June 13, 2025Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase development in weight management based on completed clinical studies The decision to advance subcutaneous and oral
